


WHAT IS CLAIMED IS:

1. A compound structurally represented by Formula I



(I)

or pharmaceutically acceptable salts thereof wherein:

G¹ is -CH₂-, or -CH₂-CH₂-,

10 G² is -CH₂-, or -C(O)-,

or G¹ and G² taken together combine to form -CH=CH- or -CH₂-CH=CH-,


Y is

- OCH₂CH₂N-piperidinyl,
 15 -OCH₂CH₂CH₂N-piperidinyl,
 -OCH₂CH₂N-pyrrolidinyl,
 -OCH₂CH₂CH₂N-pyrrolidinyl,

X is H, -COR³, -CH₂R⁴, -SO₂R⁵,

R³ is

- 20 -(C₁-C₈) alkyl, optionally substituted with 1 to 3 halogens,
 -(C₃-C₈) cycloalkyl, optionally substituted with 1 to 3 halogens,
 -O(C₁-C₈) alkyl, optionally substituted with 1 to 3 halogens,



, wherein R^6 is $-(C_1-C_6)$ alkyl, or $-COO-(C_1-C_6)$ alkyl,

-Furanyl,

-Thienyl,

-NH-phenyl,

5 -NH- (C_1-C_4) alkyl-phenyl,

-NH- (C_1-C_8) alkyl, optionally substituted with 1 to 4 halogens,

-NH- (C_3-C_8) cycloalkyl, optionally substituted once or twice with halogens,

-CH₂-Pyridinyl,

-CH₂N (C_1-C_6) alkyl (C_1-C_6) alkyl,

10 -CH₂N-phenyl,

R^4 is

- (C_1-C_8) alkyl, optionally substituted with 1 to 4 halogens,

- (C_3-C_8) cycloalkyl,

- (C_1-C_8) alkyl-NH₂,

15 - (C_1-C_4) alkyl -phenyl,

-CH₂N-phenyl,

-phenyl-O- (C_1-C_4) alkyl -phenyl,

- (C_1-C_4) alkyl-O- (C_1-C_4) alkyl-phenyl,

-CH₂NCO₂- (C_1-C_6) alkyl,


20 -Phenyl,

-Thienyl,

-Furanyl,

-Imidazolyl,

-Naphthyl,



, wherein R^6 is $-(C_1-C_6)$ alkyl, or $-COO-(C_1-C_6)$ alkyl,

-Biphenyl, and

R^5 is

-Phenyl,

5

$-(C_1-C_4)$ alkyl,

$-(C_1-C_4)$ alkyl -phenyl.

2. The compound of claim 1, wherein $G1$ is $-CH_2-$.

3. The compound of claim 1, wherein $G1$ $-CH_2-CH_2-$.

4. The compound of claim 2, wherein Y is in the 5 position.







10






5. The compound of claim 3, wherein Y is in the 6 position.







6. The compound of claim 4, wherein X is $-COR^3$.







7. The compound of claim 1, selected from the group consisting of:






	Example Number	Structure	
	1		
	2		
	3		






	4		
	5		
	6		
	7		
	8		
	9		






	10	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)CN(C3)CC4CCCCC4</chem>	
	11	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)N(S(=O)(=O)c4ccccc4)CC3</chem>	
	12	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)N(C(=O)OC(C)(C)C)CC3</chem>	
	13	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)NCC3</chem>	
	14	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)N(CC)CC3</chem>	





	15		
	16		
	17		
	18		
	19		
	20		






	21	 <chem>ClC1=CC=C2C(=C1)C(=CN2)OCCN3CCCCC3Cl</chem>	
	22	 <chem>C1CCN(C1)OCCOCC2=CC=C3C(=C2)C(=CN3)CCN4CCCCC4</chem>	
	23	 <chem>c1ccccc1CN2C(=CN2C3=CC=CC=C3)C4=CC=C5C(=C4)C(=CN5)OCCN6CCCCC6</chem>	
	24	 <chem>ClC1=CC=C2C(=C1)C(=CN2)C3=CC=C(C(=C3)Cl)OCCN4CCCCC4C5=CN=C5</chem>	
	25	 <chem>C1CCN(C1)OCCOCC2=CC=C3C(=C2)C(=CN3)CCN4CCCCC4C5=CC=C(S5)</chem>	
	26	 <chem>C1CCN(C1)OCCOCC2=CC=C3C(=C2)C(=CN3)CCN4CCCCC4C5=CC=C(S5)</chem>	






	27		
	28		
	29		
	30		
	31		






	32		
	33		
	34		
	35		
	36		





	37		
	38		
	39		
	40		
	41		

	42		
	43		
	44		
	45		

	46		
	47		
	48		
	49		
	50		

	51	 <p>Chiral</p>	
	52	 <p>Chiral</p>	
	53		
	54		
	55		

	56		
	57	 Chiral	
	58		
	59	 Chiral	
	60	 Chiral	

	61		
	62		
	63		
	64		

or a pharmaceutically acceptable salt or solvate thereof.

8. A pharmaceutical composition which comprises a compound of any of claims 1-7 and a pharmaceutically acceptable carrier.
- 5 9. A method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H₃ receptor, said antagonists comprising a compound of any of claims 1-7.
10. The method of Claim 9 wherein the antagonist is a pharmaceutical composition of claim 8.
- 10 11. The method of Claim 9 wherein the antagonist is characterized by selectively binding the histamine H₃R receptor, relative to the histamine H₄R receptor.

12. A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of Claims 1-7.
13. The method of Claim 12 wherein the antagonist is a pharmaceutical composition of claim 8.
14. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of claims 1-7.